title: Impact of an exercise program on muscular and functional performance and plasma levels of interleukin 6 and soluble receptor tumor necrosis factor in prefrail community-dwelling older women: a randomized controlled trial.
abstract: OBJECTIVE
  To examine the impact of a muscle resistance program (MRP) on muscular and functional performance and on interleukin 6 (IL-6) and soluble tumor necrosis factor receptor-1 (sTNFr1) plasma levels in prefrail community-dwelling women.
  
  
  METHODS
  Randomized controlled trial crossover design with a postintervention and short-term follow-up.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  Prefrail community-dwelling women (N=32; ≥65y).
  
  
  METHODS
  The MRP was designed based on the exercise at 75% of each participant's maximum load (10wk, 3 times/wk).
  
  
  METHODS
  Plasma concentrations of IL-6 and sTNFr1 (high-sensitivity enzyme-linked immunosorbent assay kits), muscle strength of the knee extensors (isokinetic), and functional performance (Timed Up & Go [TUG] test and 10-meter walk test [10MWT]).
  
  
  RESULTS
  There were significant differences in functional and muscular performance between the pre-MRP, post-MRP, and 10-week follow-up period. After the MRP, both functional (TUG, pre-MRP=11.1s vs post-MRP=10.4s, P=.00; 10MWT, pre-MRP=4.9s vs post-MRP, 4.4s, P=.00) and muscular performances (pre-MRP=77.8% and post-MRP=83.1%, P=.02) improved. After cessation of the MRP (follow-up period), sTNFr1 plasma levels increased by 21.4% at 10-week follow-up (post-MRP, 406.4pg/mL; 10-week follow-up, 517.0pg/mL; P=.03). There were significant differences in sTNFr1 (P=.01).
  
  
  CONCLUSIONS
  The MRP was effective in improving functional and muscular performances, although alterations in plasma levels of IL-6 and sTNFr1 could not be identified after the MRP. Cessation of the MRP after 10 weeks resulted in increased plasma levels of sTNFr1.
authors.affiliation: Rehabilitation Science, Universidade Federal de Minas Gerais and Centro Universitário de Belo Horizonte, Belo Horizonte, MG, Brazil.
authors.forename: Lygia Paccini
authors.initials: LP
authors.lastname: Lustosa
authors.forename: Leani Souza
authors.initials: LS
authors.lastname: Máximo Pereira
authors.forename: Fernanda Matos
authors.initials: FM
authors.lastname: Coelho
authors.forename: Daniele Sirineu
authors.initials: DS
authors.lastname: Pereira
authors.forename: Juscélio Pereira
authors.initials: JP
authors.lastname: Silva
authors.forename: Adriana Netto
authors.initials: AN
authors.lastname: Parentoni
authors.forename: Rosângela Correa
authors.initials: RC
authors.lastname: Dias
authors.forename: João Marcos
authors.initials: JM
authors.lastname: Domingues Dias
mesh_terms: D000367:Age Factors; D000368:Aged; D015331:Cohort Studies; D018592:Cross-Over Studies; D005080:Exercise Test; D005260:Female; D006304:Health Status; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D053580:Muscle Strength / Q000502:physiology*; D010807:Physical Endurance / Q000502:physiology*; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000097:blood*; D055070:Resistance Training; D012737:Sex Factors; D013997:Time Factors
chemical_list: D015850:Interleukin-6; D047888:Receptors, Tumor Necrosis Factor, Type I